This article is more than 5 years old. Information may no longer be current.

Iantech reaps investment to advance cataract surgery tool

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Two investment funds have invested in Iantech to further advance its miLOOP technology, according to a press release from Global Health Investment Fund.

The investments, of undisclosed amounts, by both the Visionary Venture Fund and the Global Health Investment Fund will be used for further research and development and commercial efforts for miLOOP, according to the release.

Developed by Sean Ianchulev, MD, MPH, co-founder of Iantech, the miLOOP is a pen-like device intended for use in cataract surgery. Its nitinol micro-filament technology allows “energy-free lens fragmentation through a minimally invasive clear cornea incision,” the release said.

“We are excited to partner with Iantech to bring miLOOP to the U.S. and global markets,” Curt LaBelle, managing partner at Global Health Investment Fund, said in the release. “Our mandate is to support companies that can make a tangible difference in lives globally, and miLOOP’s potential to help erase global blindness fits that perfectly.”